Doseology Announces Resignation of Director
Doseology Sciences (DOSEF) announced that Larry Latowsky has resigned as a company director, with the resignation effective immediately.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Doseology Sciences (DOSEF) announced that Larry Latowsky has resigned as a company director, with the resignation effective immediately.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kelowna, British Columbia--(Newsfile Corp. - October 14, 2026) - Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announces that Larry Latowsky has resigned as a director of the Company, effective immediately.
About Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70)
Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.
From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.
For more information visit:
Corporate: www.doseology.com
On behalf of the Board of Directors,
Kareem Baalbaki
Interim CEO
Doseology Sciences Inc.
Investor & Media Contact:
Email: hello@doseology.com
Phone: 825.800.0115
No securities regulatory authority has either approved or disapproved of the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319077